China Metastatic Liver Cancer Clinical Registry Cohort Database

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Study Overview

• Status: Recruiting
• Conditions: Liver Diseases; Neoplasms; Colorectal Cancer Metastatic; Liver Metastases; Liver Cancer; Metastases to Liver
• Intervention / Treatment: Procedure: Standard of Care for Metastatic Liver Cancer

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Lianxin Liu, MD PhD; Phone Number: +86 13845159888; Email: liulx@ustc.edu.cn
• Study Contact Backup: Name: Jizhou Wang, MD PhD; Phone Number: +86 13836135864; Email: wangjoe@ustc.edu.cn

Study Locations

• China
  • Anhui
    • Bengbu, Anhui, China, 230001
      • Not yet recruiting
      • The First Affiliated Hospital of Bengbu Medical University
      • Contact: Zheng Lu; Phone Number: +86 13721179461; Email: luzhengdr@163.com
    • Hefei, Anhui, China, 230001
      • Recruiting
      • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
      • Contact: Jizhou Wang; Phone Number: +86 13836135864; Email: wangjoe@ustc.edu.cn
  • Shandong
    • Qingdao, Shandong, China, 266003
      • Recruiting
      • The Affiliated Hospital of Qingdao University
      • Contact: Bing Han, MD PhD; Email: hanbing@qduhospital.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).

Description

Inclusion Criteria:

1. Patients with histologically or radiologically confirmed metastatic liver cancer.
2. Age ≥ 18 years.
3. Patients who have voluntarily signed the informed consent form.
4. Patients with complete baseline clinical data.

Exclusion Criteria:

1. Patients with primary liver cancer (e.g., hepatocellular carcinoma).
2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
3. Patients who have previously participated in other interventional clinical trials.
4. Patients with severe cognitive disorders or communication barriers that prevent informed consent.
5. Patients with incomplete or missing key clinical data.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.	Up to 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival	Description: The time interval from the date of enrollment (or initial treatment) to the date of the first documented disease progression (local recurrence or distant metastasis) or death from any cause, whichever occurs first.	Up to 10 years
Treatment-Related Adverse Events	The incidence and severity of postoperative complications or treatment-related adverse events, graded according to the Clavien-Dindo classification (for surgical complications) or CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.	Within 90 days post-treatment

Collaborators and Investigators

• Sponsor: Anhui Provincial Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): May 31, 2031
• Study Completion (Estimated): May 31, 2036

Study Registration Dates

• First Submitted: May 16, 2026
• First Submitted That Met QC Criteria: May 16, 2026
• First Posted (Actual): May 22, 2026

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 16, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Liver Metastases; Metastatic Colorectal Cancer
• Additional Relevant MeSH Terms: Neoplasms by Site; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Liver Diseases; Health Services Administration; Health Care Quality, Access, and Evaluation; Quality of Health Care; Quality Indicators, Health Care; Standard of Care
• Other Study ID Numbers: 2025KY534

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Individual participant data will not be made publicly available due to patient privacy and ethical restrictions. However, de-identified data may be shared with researchers who provide a methodologically sound proposal and have appropriate ethical approvals, subject to the approval of the study steering committee. Requests should be directed to the corresponding author.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No